title: [Advances of transforming growth factor-β inhibitors].
abstract: Transforming growth factor-β is an important cytokine with various bioactivities, including embryonic development, wound healing, chemotaxis and cell cycle regulation. Epithelial-mesenchymal transition (EMT) is the main pathway of tumor cell to obtain the ability of invasion and metastasis. The TGF-β is the key factor known to induce EMT in cancer cells and plays an important role in the process. In recent years, some progress has been obtained. Some TGF-β inhibitors have approved in the market or in clinical trials. TGF-β inhibitors can play an important role on the treatment of tumors, glaucoma, liver and kidney fibrosis disease and scar repair. Novel TGF-β inhibitors reported in recent years were reviewed in this article.
authors.forename: Xiao-xiong
authors.initials: XX
authors.lastname: Ge
authors.forename: Qi-fan
authors.initials: QF
authors.lastname: Zhou
authors.forename: Guo-liang
authors.initials: GL
authors.lastname: Chen
mesh_terms: D058750:Epithelial-Mesenchymal Transition; D006801:Humans; D009369:Neoplasms; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors*; D014945:Wound Healing
chemical_list: D016212:Transforming Growth Factor beta